Charles Schwab Investment Management Inc. Acquires 157,135 Shares of Immunome, Inc. $IMNM

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Immunome, Inc. by 34.4%, owning 614,387 shares valued at approximately $4.13 million.
• Institutional investors currently hold 44.58% of Immunome's stock, with several other firms also increasing their positions recently.
• Eight research analysts have rated Immunome with a Buy rating and an average price target of $22.50, indicating positive market sentiment toward the company.

Charles Schwab Investment Management Inc. raised its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 34.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 614,387 shares of the company's stock after buying an additional 157,135 shares during the period. Charles Schwab Investment Management Inc. owned 0.71% of Immunome worth $4,135,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Immunome by 24.2% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 51,544 shares of the company's stock worth $347,000 after acquiring an additional 10,039 shares during the last quarter. Two Sigma Investments LP purchased a new stake in Immunome in the 4th quarter worth $1,640,000. ProShare Advisors LLC purchased a new position in shares of Immunome during the 4th quarter worth about $154,000. MetLife Investment Management LLC lifted its holdings in shares of Immunome by 17.7% during the 4th quarter. MetLife Investment Management LLC now owns 35,619 shares of the company's stock valued at $378,000 after purchasing an additional 5,354 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Immunome by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 26,207 shares of the company's stock valued at $278,000 after purchasing an additional 8,190 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Stock Performance

Shares of NASDAQ IMNM traded down $0.39 during mid-day trading on Friday, reaching $9.51. 684,063 shares of the company traded hands, compared to its average volume of 646,397. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $16.73. The company's fifty day moving average is $9.78 and its two-hundred day moving average is $8.85. The stock has a market cap of $827.75 million, a PE ratio of -3.09 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.02. The firm had revenue of $4.02 million during the quarter, compared to analysts' expectations of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. Research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insider Activity at Immunome

In related news, Director Jean Jacques Bienaime bought 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were bought at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the acquisition, the director directly owned 36,415 shares of the company's stock, valued at $341,572.70. This trade represents a 15.92% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.69% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IMNM shares. Wall Street Zen upgraded Immunome from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Evercore ISI started coverage on Immunome in a research report on Friday, August 22nd. They issued an "outperform" rating and a $18.00 target price on the stock. Guggenheim reiterated a "buy" rating and issued a $25.00 price objective on shares of Immunome in a research note on Monday, August 25th. Wedbush restated an "outperform" rating and set a $21.00 price target on shares of Immunome in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. lowered their target price on Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $22.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.